Lourd Capital LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 6.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,883 shares of the company’s stock after buying an additional 366 shares during the quarter. Lourd Capital LLC’s holdings in Eli Lilly and were worth $484,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Heritage Trust Co bought a new position in shares of Eli Lilly and in the 1st quarter worth about $135,000. Point72 Asia Hong Kong Ltd raised its position in shares of Eli Lilly and by 237.4% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after acquiring an additional 1,239 shares in the last quarter. Cornerstone Advisors Inc. raised its position in shares of Eli Lilly and by 18.4% in the 2nd quarter. Cornerstone Advisors Inc. now owns 2,013 shares of the company’s stock worth $166,000 after acquiring an additional 313 shares in the last quarter. Penserra Capital Management LLC raised its position in shares of Eli Lilly and by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after acquiring an additional 176 shares in the last quarter. Finally, American National Bank raised its position in shares of Eli Lilly and by 5.2% in the 2nd quarter. American National Bank now owns 2,088 shares of the company’s stock worth $172,000 after acquiring an additional 104 shares in the last quarter. 75.72% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have recently weighed in on LLY shares. Sanford C. Bernstein reissued an “outperform” rating and issued a $88.00 price objective on shares of Eli Lilly and in a research report on Sunday, May 21st. Jefferies Group LLC reissued a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, May 30th. TheStreet lowered Eli Lilly and from a “b+” rating to a “c” rating in a research report on Wednesday, May 31st. BidaskClub raised Eli Lilly and from a “sell” rating to a “hold” rating in a research report on Wednesday, June 14th. Finally, Zacks Investment Research lowered Eli Lilly and from a “hold” rating to a “sell” rating in a research report on Tuesday, June 27th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $88.27.

Shares of Eli Lilly and Company (NYSE:LLY) opened at 82.44 on Monday. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72. The company has a market capitalization of $86.97 billion, a price-to-earnings ratio of 35.67 and a beta of 0.34. The firm’s 50-day moving average price is $80.89 and its 200-day moving average price is $82.06.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter last year, the firm earned $0.86 earnings per share. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. Analysts anticipate that Eli Lilly and Company will post $4.16 earnings per share for the current year.

WARNING: “Lourd Capital LLC Buys 366 Shares of Eli Lilly and Company (LLY)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/18/lourd-capital-llc-buys-366-shares-of-eli-lilly-and-company-lly.html.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the transaction, the insider now owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 825,000 shares of company stock valued at $68,456,650 in the last ninety days. Insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.